RxDoctor Payments Data

Wahed Ishaqsei, MD

Internal Medicine · Roseville, MINPI 1063423176

Payments from drug & device makers

$565in general payments, 2019–2025

Across 33 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$97
  • Lundbeck LLC$61
  • Pfizer$48
  • Teva Pharmaceuticals USA, Inc.$44
  • Johnson & Johnson$41
  • Cipher Pharmaceuticals US LLC$28
  • plus $247 from 13 others

What the payments were for

  • Food & beverage$565100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$565 in reported general payments places this provider in the 65th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$213,585
Medicare patients
316
Services billed
2,156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban222$90,348
VelphoroSucroferric Oxyhydroxide16$27,226
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$27,131
TivicayDolutegravir Sodium22$24,750
JanuviaSitagliptin Phosphate29$23,795
JardianceEmpagliflozin32$16,261
EntrestoSacubitril/Valsartan34$15,257
RexultiBrexpiprazole18$13,843
LokelmaSodium Zirconium Cyclosilicate32$12,133
JanumetSitagliptin Phos/Metformin Hcl15$11,085
Breo ElliptaFluticasone/Vilanterol18$7,527
Atorvastatin Calcium520$7,520
TrulicityDulaglutide21$6,229
XareltoRivaroxaban19$5,895
Fluticasone-SalmeterolFluticasone Propion/Salmeterol31$5,582

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$48$90,348222 claims
NovartisEntresto$97$15,25734 claims
AstraZenecaLokelma$19$12,13332 claims
Lilly USA, LLCTrulicity$20$6,22921 claims
Johnson & JohnsonXarelto$41$5,89519 claims
Sumitomo Pharma America, Inc.Gemtesa$16$3,40914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Roseville

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →